Separation of antithrombin III &agr; and &bgr; variants by cyclodextrin-modified micellar electrokinetic chromatography

US6395881B1 · kind B1 · utility

Assignee

• Aventis Behring GmbH · DE

Inventors

• Reiner Doenges · Lahntal, DE
• Juergen Roemisch · Marburg, DE
• Harald Stauss · Steffenberg, DE

Key dates

• Filing date: May 7, 2001
• Grant date: May 28, 2002
• Expiry date: May 7, 2021

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N27/44747
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

A process is disclosed for the baseline separation of the &agr; and &bgr; variants of antithrombin III AT-III. The process involves subjecting a sample comprising AT III to cyclodextrin-modified micellar electrokinetic chromatography (CD-MEKC). The CD-MEKC is performed with a buffer comprising boric acid, an anionic tensid, &bgr;-cyclodextrin, and an aliphatic diamine at a basic pH. The CD-MEKC results in the separation of the AT III into AT III &agr; and ATIII &bgr;. The anionic tensid can be sodium dodecyl sulfate and the aliphatic diamine can be 1, 5-diaminopentane.